Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I studyShunji Takahashi, Noboru Yamamoto, Tomonari Yamashita et al.|Cancer Science|2021Cited by 72